Financings Of The Fortnight: Finding Comedy In Today's Financial Environment
This article was originally published in The Pink Sheet Daily
A Magic 8-Ball assesses the Sanofi/Genzyme intrigue, while Convergence, Agennix, Tobira and CtyomX highlight a busy two weeks in biotech finance.
You may also be interested in...
The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.